Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Publication
, Other
Aggarwal, R; Starodub, AN; Koh, BD; Xing, G; Armstrong, AJ; Carducci, MA
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Aggarwal, R., Starodub, A. N., Koh, B. D., Xing, G., Armstrong, A. J., & Carducci, M. A. (2023). Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. https://doi.org/10.1158/1078-0432.22487574
Aggarwal, Rahul, Alexander N. Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, and Michael A. Carducci. “Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer,” March 31, 2023. https://doi.org/10.1158/1078-0432.22487574.
Aggarwal R, Starodub AN, Koh BD, Xing G, Armstrong AJ, Carducci MA. Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. 2023.
Aggarwal, Rahul, et al. Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22487574.
Aggarwal R, Starodub AN, Koh BD, Xing G, Armstrong AJ, Carducci MA. Supplementary Data from Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. 2023.